About Us Services Careers FAQ Contact Us 0
Home Pharmaceuticals Intravenous Immunoglobulin Market Size, Share, Growth Analysis by 2030
Intravenous Immunoglobulin Market

Intravenous Immunoglobulin Market Size, Share & Trends Analysis Report By Application (Hypogammaglobulinemia, CIDP, Immunodeficiency Diseases, Congenital AIDS, Chronic Lymphocytic Leukemia, Myasthenia Gravis, Multifocal Motor Neuropathy, ITP, Kawasaki Disease, Guillain-Barre Syndrome), By Distribution Channel (Hospital Pharmacy, Specialty Pharmacy) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2022-2030

Report Code: SRPH2275DR
Last Updated : August 18, 2022
Author : Straits Research
Starting From
USD 2300
Buy Now
File Formats

Table Of Content

  1. Executive Summary
    1. Research Objectives
    2. Limitations & Assumptions
    3. Market Scope & Segmentation
    4. Currency & Pricing Considered
    1. Emerging Regions / Countries
    2. Emerging Companies
    3. Emerging Applications / End Use
    1. Drivers
    2. Market Warning Factors
    3. Latest Macro Economic Indicators
    4. Geopolitical Impact
    5. Technology Factors
    1. Porters Five Forces Analysis
    2. Value Chain Analysis
    1. North America
    2. Europe
    3. APAC
    4. Middle East and Africa
    5. LATAM
  2. ESG Trends
    1. Global Intravenous Immunoglobulin Market Introduction
    2. By Application
      1. Introduction
        1. Application By Value
      2. Hypogammaglobulinemia
        1. By Value
      3. CIDP
        1. By Value
      4. Immunodeficiency Diseases
        1. By Value
      5. Congenital AIDS
        1. By Value
      6. Chronic Lymphocytic Leukemia
        1. By Value
      7. Myasthenia Gravis
        1. By Value
      8. Multifocal Motor Neuropathy
        1. By Value
      9. ITP
        1. By Value
      10. Kawasaki Disease
        1. By Value
      11. Guillain-Barre Syndrome
        1. By Value
    3. By Distribution Channel
      1. Introduction
        1. Distribution Channel By Value
      2. Hospital Pharmacy
        1. By Value
      3. Specialty Pharmacy
        1. By Value
    1. Introduction
    2. By Application
      1. Introduction
        1. Application By Value
      2. Hypogammaglobulinemia
        1. By Value
      3. CIDP
        1. By Value
      4. Immunodeficiency Diseases
        1. By Value
      5. Congenital AIDS
        1. By Value
      6. Chronic Lymphocytic Leukemia
        1. By Value
      7. Myasthenia Gravis
        1. By Value
      8. Multifocal Motor Neuropathy
        1. By Value
      9. ITP
        1. By Value
      10. Kawasaki Disease
        1. By Value
      11. Guillain-Barre Syndrome
        1. By Value
    3. By Distribution Channel
      1. Introduction
        1. Distribution Channel By Value
      2. Hospital Pharmacy
        1. By Value
      3. Specialty Pharmacy
        1. By Value
    4. U.S.
      1. By Application
        1. Introduction
          1. Application By Value
        2. Hypogammaglobulinemia
          1. By Value
        3. CIDP
          1. By Value
        4. Immunodeficiency Diseases
          1. By Value
        5. Congenital AIDS
          1. By Value
        6. Chronic Lymphocytic Leukemia
          1. By Value
        7. Myasthenia Gravis
          1. By Value
        8. Multifocal Motor Neuropathy
          1. By Value
        9. ITP
          1. By Value
        10. Kawasaki Disease
          1. By Value
        11. Guillain-Barre Syndrome
          1. By Value
      2. By Distribution Channel
        1. Introduction
          1. Distribution Channel By Value
        2. Hospital Pharmacy
          1. By Value
        3. Specialty Pharmacy
          1. By Value
    5. Canada
    1. Introduction
    2. By Application
      1. Introduction
        1. Application By Value
      2. Hypogammaglobulinemia
        1. By Value
      3. CIDP
        1. By Value
      4. Immunodeficiency Diseases
        1. By Value
      5. Congenital AIDS
        1. By Value
      6. Chronic Lymphocytic Leukemia
        1. By Value
      7. Myasthenia Gravis
        1. By Value
      8. Multifocal Motor Neuropathy
        1. By Value
      9. ITP
        1. By Value
      10. Kawasaki Disease
        1. By Value
      11. Guillain-Barre Syndrome
        1. By Value
    3. By Distribution Channel
      1. Introduction
        1. Distribution Channel By Value
      2. Hospital Pharmacy
        1. By Value
      3. Specialty Pharmacy
        1. By Value
    4. U.K.
      1. By Application
        1. Introduction
          1. Application By Value
        2. Hypogammaglobulinemia
          1. By Value
        3. CIDP
          1. By Value
        4. Immunodeficiency Diseases
          1. By Value
        5. Congenital AIDS
          1. By Value
        6. Chronic Lymphocytic Leukemia
          1. By Value
        7. Myasthenia Gravis
          1. By Value
        8. Multifocal Motor Neuropathy
          1. By Value
        9. ITP
          1. By Value
        10. Kawasaki Disease
          1. By Value
        11. Guillain-Barre Syndrome
          1. By Value
      2. By Distribution Channel
        1. Introduction
          1. Distribution Channel By Value
        2. Hospital Pharmacy
          1. By Value
        3. Specialty Pharmacy
          1. By Value
    5. Germany
    6. France
    7. Spain
    8. Italy
    9. Russia
    10. Nordic
    11. Benelux
    12. Rest of Europe
    1. Introduction
    2. By Application
      1. Introduction
        1. Application By Value
      2. Hypogammaglobulinemia
        1. By Value
      3. CIDP
        1. By Value
      4. Immunodeficiency Diseases
        1. By Value
      5. Congenital AIDS
        1. By Value
      6. Chronic Lymphocytic Leukemia
        1. By Value
      7. Myasthenia Gravis
        1. By Value
      8. Multifocal Motor Neuropathy
        1. By Value
      9. ITP
        1. By Value
      10. Kawasaki Disease
        1. By Value
      11. Guillain-Barre Syndrome
        1. By Value
    3. By Distribution Channel
      1. Introduction
        1. Distribution Channel By Value
      2. Hospital Pharmacy
        1. By Value
      3. Specialty Pharmacy
        1. By Value
    4. China
      1. By Application
        1. Introduction
          1. Application By Value
        2. Hypogammaglobulinemia
          1. By Value
        3. CIDP
          1. By Value
        4. Immunodeficiency Diseases
          1. By Value
        5. Congenital AIDS
          1. By Value
        6. Chronic Lymphocytic Leukemia
          1. By Value
        7. Myasthenia Gravis
          1. By Value
        8. Multifocal Motor Neuropathy
          1. By Value
        9. ITP
          1. By Value
        10. Kawasaki Disease
          1. By Value
        11. Guillain-Barre Syndrome
          1. By Value
      2. By Distribution Channel
        1. Introduction
          1. Distribution Channel By Value
        2. Hospital Pharmacy
          1. By Value
        3. Specialty Pharmacy
          1. By Value
    5. Korea
    6. Japan
    7. India
    8. Australia
    9. Taiwan
    10. South East Asia
    11. Rest of Asia-Pacific
    1. Introduction
    2. By Application
      1. Introduction
        1. Application By Value
      2. Hypogammaglobulinemia
        1. By Value
      3. CIDP
        1. By Value
      4. Immunodeficiency Diseases
        1. By Value
      5. Congenital AIDS
        1. By Value
      6. Chronic Lymphocytic Leukemia
        1. By Value
      7. Myasthenia Gravis
        1. By Value
      8. Multifocal Motor Neuropathy
        1. By Value
      9. ITP
        1. By Value
      10. Kawasaki Disease
        1. By Value
      11. Guillain-Barre Syndrome
        1. By Value
    3. By Distribution Channel
      1. Introduction
        1. Distribution Channel By Value
      2. Hospital Pharmacy
        1. By Value
      3. Specialty Pharmacy
        1. By Value
    4. UAE
      1. By Application
        1. Introduction
          1. Application By Value
        2. Hypogammaglobulinemia
          1. By Value
        3. CIDP
          1. By Value
        4. Immunodeficiency Diseases
          1. By Value
        5. Congenital AIDS
          1. By Value
        6. Chronic Lymphocytic Leukemia
          1. By Value
        7. Myasthenia Gravis
          1. By Value
        8. Multifocal Motor Neuropathy
          1. By Value
        9. ITP
          1. By Value
        10. Kawasaki Disease
          1. By Value
        11. Guillain-Barre Syndrome
          1. By Value
      2. By Distribution Channel
        1. Introduction
          1. Distribution Channel By Value
        2. Hospital Pharmacy
          1. By Value
        3. Specialty Pharmacy
          1. By Value
    5. Turkey
    6. Saudi Arabia
    7. South Africa
    8. Egypt
    9. Nigeria
    10. Rest of MEA
    1. Introduction
    2. By Application
      1. Introduction
        1. Application By Value
      2. Hypogammaglobulinemia
        1. By Value
      3. CIDP
        1. By Value
      4. Immunodeficiency Diseases
        1. By Value
      5. Congenital AIDS
        1. By Value
      6. Chronic Lymphocytic Leukemia
        1. By Value
      7. Myasthenia Gravis
        1. By Value
      8. Multifocal Motor Neuropathy
        1. By Value
      9. ITP
        1. By Value
      10. Kawasaki Disease
        1. By Value
      11. Guillain-Barre Syndrome
        1. By Value
    3. By Distribution Channel
      1. Introduction
        1. Distribution Channel By Value
      2. Hospital Pharmacy
        1. By Value
      3. Specialty Pharmacy
        1. By Value
    4. Brazil
      1. By Application
        1. Introduction
          1. Application By Value
        2. Hypogammaglobulinemia
          1. By Value
        3. CIDP
          1. By Value
        4. Immunodeficiency Diseases
          1. By Value
        5. Congenital AIDS
          1. By Value
        6. Chronic Lymphocytic Leukemia
          1. By Value
        7. Myasthenia Gravis
          1. By Value
        8. Multifocal Motor Neuropathy
          1. By Value
        9. ITP
          1. By Value
        10. Kawasaki Disease
          1. By Value
        11. Guillain-Barre Syndrome
          1. By Value
      2. By Distribution Channel
        1. Introduction
          1. Distribution Channel By Value
        2. Hospital Pharmacy
          1. By Value
        3. Specialty Pharmacy
          1. By Value
    5. Mexico
    6. Argentina
    7. Chile
    8. Colombia
    9. Rest of LATAM
    1. Intravenous Immunoglobulin Market Share By Players
    2. M&A Agreements & Collaboration Analysis
    1. Baxalta Incorporated
      1. Overview
      2. Business Information
      3. Revenue
      4. ASP
      5. SWOT Analysis
      6. Recent Developments
    2. Biotest AG
    3. China Biologic Products Inc.
    4. CSL Behring LLC
    5. Grifols S.A.
    6. Kedrion S.p.A.
    7. LFB Biomedicaments S.A.
    8. Octapharma AG
    9. Sanquin Plasma Products B.V.
    10. Bharat Serums and Vaccines Limited
    1. Research Data
      1. Secondary Data
        1. Major secondary sources
        2. Key data from secondary sources
      2. Primary Data
        1. Key data from primary sources
        2. Breakdown of primaries
      3. Secondary And Primary Research
        1. Key industry insights
    2. Market Size Estimation
      1. Bottom-Up Approach
      2. Top-Down Approach
      3. Market Projection
    3. Research Assumptions
      1. Assumptions
    4. Limitations
    5. Risk Assessment
    1. Discussion Guide
    2. Customization Options
    3. Related Reports
  3. Disclaimer

Related Reports

Global Report
The immunoglobulin market size was valued at USD 13,799.45 million in 2022. It is expected to reach USD 24,446.1 million by 2030, growing at a CAGR of 6.56% during the forecast period (2023–2031). Immunoglobulins are a group of glycoprotein mo
Buy Now

Purchase Benefits

  • Eligible for a free updated report next year
  • Completely customizable scope
  • 30% discount on your next purchase
  • Dedicated account manager
  • Query resolution within 24 hours
  • Permission to print the report

We are featured on :

www.straitsresearch.com
© Copyright 2025. All rights Reserved.